Biodexa stock rallies amid release of Phase 2 data for eRapa (NASDAQ:BDRX)
2024-07-11
ibreakstock/iStock via Getty Images Biodexa (NASDAQ:BDRX) stock shot up 70% in morning trading Thursday after the company re-released positive data from a Phase 2 study for its drug eRapa in the treatment of Familial Adenomatous Polyposis, for FAP. According to the company’s release Thursday, 12-month data from the Phase 2Continue Reading